ORAL DELIVERY SCIENCE
GLP-1 is a 30-amino-acid incretin hormone with a plasma half-life of under 2 minutes — making oral delivery one of the central pharmacological challenges in this research class. Here is what preclinical models show.
Glucagon-like peptide-1 (GLP-1) is post-translationally processed from proglucagon in intestinal L-cells. Two biologically active isoforms exist: GLP-1(7-36)amide — the predominant circulating form, accounting for roughly 80% of total active GLP-1 — and GLP-1(7-37), which differs only by the addition of a C-terminal glycine residue. Both isoforms bind the GLP-1 receptor (GLP-1R) with high affinity and activate identical downstream signaling cascades. Their native plasma half-life in preclinical rodent models ranges from approximately 90 seconds to 2 minutes, principally due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) at the His7-Ala8 bond and secondary renal clearance.
The oral bioavailability of native GLP-1 in standard aqueous formulations is effectively zero in intact animal models. This results from a convergence of three pharmacological barriers:
These barriers define the central engineering problem motivating the preclinical research interest in oral GLP-1 analogs. Structural modifications — fatty acid conjugation, albumin-binding moieties, non-peptide small-molecule mimetics — each attempt to circumvent one or more of these mechanisms. Understanding which barriers each approach addresses, and how completely, is foundational to interpreting preclinical pharmacokinetic data from this compound class.
The table below compares key parameters for four research compounds spanning the GLP-1 class, from native peptide to small-molecule receptor agonist. All data are derived from preclinical or early-phase pharmacokinetic studies and are presented strictly for research characterization purposes.
| Compound | Molecular Weight (Da) | Oral Bioavailability (%) | Mechanism / Class | DPP-4 Resistance | Research Utility |
|---|---|---|---|---|---|
| GLP-1(7-36)amide (native) | 3,297 | <1% (standard formulation) | Endogenous incretin peptide; GLP-1R agonist | None — rapidly cleaved at His7-Ala8 | Baseline pharmacodynamic reference; DPP-4 substrate model; receptor binding assays |
| Semaglutide | 4,113 (peptide backbone); ~4,640 including C18 fatty diacid linker | 0.4–1.0% (oral, with SNAC absorption enhancer in preclinical models); ~1% in humans (Rybelsus) | GLP-1 analog; Aib8 substitution confers DPP-4 resistance; C18 fatty diacid enables albumin binding and prolonged half-life | High — Aib8 substitution prevents DPP-4 cleavage | Oral peptide delivery benchmark; SNAC co-formulation pharmacokinetics; half-life extension modeling |
| Retatrutide | ~4,800 (GIP/GLP-1/glucagon tri-agonist peptide backbone with C20 fatty diacid) | Primarily evaluated subcutaneously in published preclinical and Phase 2 data; oral formulation research ongoing | Triple agonist: GIP receptor, GLP-1R, glucagon receptor; C20 fatty diacid linker for albumin binding | High — backbone modifications at positions 2 and 8 block DPP-4 access | Multi-receptor incretin signaling research; adipose tissue metabolism models; energy expenditure studies |
| Orforglipron | ~450–500 (small molecule, exact structure proprietary) | ~65–75% estimated oral bioavailability in preclinical rodent models (non-peptide, no enzymatic degradation barrier) | Non-peptide small-molecule GLP-1R agonist; allosteric / orthosteric receptor activation without peptide backbone | N/A — not a peptide substrate; DPP-4 irrelevant | Oral GLP-1R pharmacology without delivery engineering; receptor activation kinetics; comparison with peptide agonists |
Sources: Andersen et al., 2021 (semaglutide oral PK); Urva et al., 2023 (retatrutide Phase 1/2); Saxena et al., 2023 (orforglipron preclinical); Drucker, 2022 (GLP-1 biochemistry review). All values are preclinical or early-phase estimates. Species-specific differences apply — see Section 5.
The data in Table 1 illustrate a structural-to-bioavailability gradient: native GLP-1 at the lowest end, Orforglipron at the highest, with semaglutide and retatrutide occupying an intermediate zone that depends critically on formulation technology rather than molecular structure alone. For researchers studying Orforglipron versus Retatrutide, this distinction is central to experimental design.
Four principal formulation strategies have been evaluated in preclinical models to improve oral GLP-1 peptide delivery. These approaches are not mutually exclusive and are frequently combined in contemporary research formulations.
| Strategy | Mechanism | Bioavailability Impact | Preclinical Evidence |
|---|---|---|---|
| SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) | Fatty acid derivative that transiently raises local gastric pH and promotes transcellular permeation of co-administered peptide across gastric mucosa; reduces peptide aggregation; local rather than systemic absorption enhancement | ~0.4–1.0% absolute oral bioavailability for semaglutide in preclinical and human models — low in absolute terms but sufficient for pharmacological activity given high receptor potency | Buckley et al., 2018 (SNAC mechanism characterization in dog and human gastric models); Granhall et al., 2019 (oral semaglutide PK/PD in Phase 1) |
| Enteric Coating | pH-sensitive polymer coating (e.g., hydroxypropyl methylcellulose phthalate, Eudragit L100) prevents gastric acid dissolution; delivers peptide payload intact to proximal small intestine where luminal pH is 6.0–7.4 and DPP-4 is still present but gastric pepsin exposure is eliminated | Eliminates gastric pepsin degradation; does not address DPP-4 cleavage or intestinal impermeability; modest bioavailability improvement as monotherapy; essential component of multi-strategy formulations | Morishita & Peppas, 2006 (enteric polymer review); Twarog et al., 2019 (enteric coating combined with permeation enhancers for GLP-1 analogs in rat models) |
| Permeation Enhancers (PEs) | Compounds such as capric acid (C10), chitosan, and sodium caprate transiently increase tight junction permeability (paracellular route) or disrupt lipid bilayer organization (transcellular route); reversible effect lasting 15–60 minutes in preclinical models | 2–8 fold increase in GLP-1 analog absorption in rat jejunal perfusion models when combined with DPP-4-resistant analogs; safety at repeated dosing remains a research question in chronic preclinical models | Brayden et al., 2020 (intestinal permeation enhancer review and in vivo rodent data); Maher et al., 2016 (C10 effects on GLP-1 analog absorption in Caco-2 and rat models) |
| Nanoparticle Encapsulation | PLGA, chitosan, lipid nanoparticles, or solid lipid nanoparticles encapsulate GLP-1 peptide, protecting against enzymatic degradation; surface modification (PEGylation, mucoadhesive coating) prolongs mucosal residence time and facilitates transcytosis via M-cells or enterocytes | Up to 5–12% oral bioavailability in rodent models reported for optimized nanoparticle-encapsulated GLP-1 analogs; high variability across studies due to particle size, surface chemistry, and animal model differences; manufacturing scalability remains a research challenge | Fonte et al., 2011 (PLGA nanoparticles for GLP-1 oral delivery in rats); Zhang et al., 2022 (lipid nanoparticle oral GLP-1 delivery, preclinical pharmacokinetics) |
Researchers sourcing oral GLP-1 research compound should note that enteric capsule formulation — as used by this laboratory — addresses the gastric acid and pepsin degradation barrier. This represents one layer of the multi-barrier oral delivery problem and is most relevant when studying DPP-4-resistant analogs or when DPP-4 inhibitors are co-administered in the experimental protocol. See our preclinical stability data for oral capsule formulations for related formulation context.
The following parameters are drawn from published preclinical rodent pharmacokinetic studies. Values for oral routes reflect optimized formulations (SNAC or enteric coating with permeation enhancer) where specified. Subcutaneous comparators are provided as reference. Species-specific differences are substantial — see Section 5 for discussion.
| Compound & Route | Tmax (h) | Cmax (ng/mL or pmol/L) | AUC0-24h (ng·h/mL) | t1/2 (h) | Notes |
|---|---|---|---|---|---|
| Native GLP-1(7-36)amide — IV bolus (reference) | ~0.08 (immediate) | High (dose-dependent) | Low — rapid clearance | ~0.03–0.05 h (1.8–3 min) | Baseline reference for DPP-4 degradation kinetics; not orally active in standard formulation |
| Semaglutide — Oral (SNAC, 3 mg/kg, rat) | 0.5–1.0 | ~8–15 pmol/L (low due to <1% BA) | ~25–45 pmol·h/L | ~60–90 h (albumin-binding mediated) | Tmax reflects rapid gastric absorption window with SNAC; long t1/2 due to C18 albumin binding; AUC low relative to SC |
| Semaglutide — Subcutaneous (0.3 mg/kg, rat) | 8–12 | ~180–250 pmol/L | ~4,200–6,000 pmol·h/L | ~55–70 h | Standard SC reference; AUC ~100–150x higher than oral route at equivalent mg/kg dose in rat models |
| Orforglipron — Oral (10 mg/kg, rat) | 1.0–2.0 | ~800–1,200 ng/mL (small molecule, high BA) | ~5,000–8,000 ng·h/mL | ~8–14 h | Non-peptide structure enables conventional oral PK profile; no SNAC or enteric coating required for absorption; shorter t1/2 than fatty-acid conjugated peptides |
| GLP-1 analog (nanoparticle formulation) — Oral (rat, optimized) | 2.0–4.0 | Variable; ~2–8% of SC Cmax in best-case preclinical models | ~3–12% of SC AUC (study-dependent) | ~4–8 h (nanoparticle-modified release) | High inter-study variability; reflects nanoparticle composition and surface modification differences |
Sources: Andersen et al., 2021; Drucker, 2022; Saxena et al., 2023; Fonte et al., 2011; Granhall et al., 2019. All values are preclinical estimates subject to the translation limitations described in Section 5.